Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.61 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | HPGDS | O60760 | 1/20 | 0.57 |
| ▸ | ESRRG | P62508 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910293 | 0.85 | HSD17B1 (0.61) | POLBRAB9AMEN1KMT2AHSD17B1 | |
| SCHEMBL12348717 | 0.84 | HSD17B1 (0.56) | POLBRAB9AMEN1KMT2AHSD17B1 | |
| SCHEMBL2491267 | 0.82 | RAB9A (1.00) | POLBRAB9AMEN1KMT2AKDM4E | |
| SCHEMBL10963422 | 0.82 | RAB9A (0.72) | POLBRAB9AMEN1KMT2AKDM4E | |
| SCHEMBL422509 | 0.82 | RAB9A (0.72) | POLBRAB9AMEN1KMT2AKDM4E | |
| SCHEMBL29906336 | 0.82 | RAB9A (0.79) | POLBRAB9AMEN1KMT2AKDM4E | |
| SCHEMBL2083801 | 0.82 | MEN1 (0.72) | POLBRAB9AMEN1KMT2AHSD17B1 | |
| SCHEMBL5842337 | 0.82 | HPGDS (0.69) | POLBRAB9AMEN1KMT2AHSD17B1 | |
| SCHEMBL1761545 | 0.82 | RAB9A (0.92) | POLBRAB9AMEN1KMT2AKDM4E | |
| SCHEMBL24573360 | 0.81 | HDAC1 (0.69) | RAB9AHSD17B1HSD17B2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | claimed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-20220202772-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-06-30 | — | — | US | disclosed |
| CN-107033095-B | The Oxazolidinone derivative of the structure of hydrazone containing piperazine | 沈阳红旗制药有限公司 | 2019-05-07 | — | — | CN | disclosed |
| CN-105228982-B | 3-acetylamino-1- (phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino) benzene derivatives for the treatment of hyperproliferative disorders | 拜耳制药股份公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107151255-A | Boric acid compound and its production and use | 复旦大学 | 2017-09-12 | — | — | CN | disclosed |
| CN-107033095-A | The Jie Gou oxazolidinone compounds of hydrazone containing piperazine | 沈阳红旗制药有限公司 | 2017-08-11 | — | — | CN | disclosed |
| CN-105228982-A | 3-acetylamino-1- (phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino) benzene derivatives for the treatment of hyperproliferative disorders | Bayer Pharma AG | 2016-01-06 | — | — | CN | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| EP-0259972-B1 | HETEROCYCLIC PROPENE AMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | LILLY INDUSTRIES LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| EP-0259972-A2 | Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202772-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS | RACK1, RRBP1, RPL30 | POLB 903/4885RAB9A 1823/4885MEN1 4218/4885 |
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | POLB 3103/4885RAB9A 3129/4885MEN1 3552/4885 |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | POLB 4496/4885RAB9A 1154/4885MEN1 550/4885 |
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | POLB 3466/4885RAB9A 2463/4885MEN1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.